Stockscreener 앱 받기
14.61
0.75%
-0.11
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? - MSN
Learn to Evaluate (ARQT) using the Charts - news.stocktradersdaily.com
Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - The Manila Times
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Is Breakeven Near? - simplywall.st
Arcutis Biotherapeutics Appoints New Chief Financial Officer - MSN
Arcutis Announces Chief Financial Officer Transition | ARQT Stoc - GuruFocus
Arcutis Biotherapeutics (ARQT) Announces CFO Transition - GuruFocus
Arcutis Biotherapeutics (ARQT) Announces Transition in CFO Role - GuruFocus
Arcutis Names New Chief Financial Officer - Contract Pharma
Arcutis CFO David Topper retires, Latha Vairavan steps in By Investing.com - Investing.com India
Arcutis Announces Chief Financial Officer Transition - BioSpace
Arcutis Biotherapeutics Names New Chief Financial Officer - marketscreener.com
Arcutis CFO David Topper retires, Latha Vairavan steps in - Investing.com Australia
Psoriasis Pipeline Analysis and Clinical Trials Assessment, - openPR.com
Arcutis at Needham Conference: Strategic Growth in Dermatology By Investing.com - Investing.com Canada
Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - MSN
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Strengthens Team with Strategic Stock Grants to 5 Key New Hires - Stock Titan
(ARQT) Trading Report - news.stocktradersdaily.com
Arcutis stock holds buy rating, $19 target amid patent case By Investing.com - Investing.com Australia
Arcutis Biotherapeutics director sells $151,236 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics director sells $151,236 in stock - Investing.com India
Recent Insider Transactions at Arcutis Biotherapeutics - TradingView
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews - Benzinga
Arcutis stock holds buy rating, $19 target amid patent case - Investing.com
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus
Arcutis stock rises following litigation stay By Investing.com - Investing.com Canada
Arcutis and Padagis agree to stay patent litigation By Investing.com - Investing.com South Africa
Arcutis And Padagis Agree To Stay Patent Lawsuit - MarketScreener
Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha
Arcutis rises after halting patent dispute with Padagis - TradingView
Arcutis Agrees to Stay Patent Lawsuit Against Padagis - MarketScreener
Arcutis and Padagis Agree to Stay Patent Lawsuit - The Manila Times
Arcutis and Padagis agree to stay patent litigation - Investing.com
Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan
Arcutis: An Agent of Patient-Centric Transformation - Technology Magazine
Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com
0.24%
36.06%
자본화:
|
볼륨(24시간):